ID
13564
Description
Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00081822
Lien
https://clinicaltrials.gov/show/NCT00081822
Mots-clés
Versions (1)
- 16/02/2016 16/02/2016 -
Détendeur de droits
CC BY-NC 3.0
Téléchargé le
16 février 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Acute Myeloid Leukemia NCT00081822
Eligibility Acute Myeloid Leukemia NCT00081822
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
patients with pre-existing myelodysplastic syndrome, or with antecedent hematologic disorder of >3 months duration, will be excluded. those with concomitant myelodysplasia/trilineage dysplasia noted at the time of diagnosis of aml will be eligible 74
Type de données
boolean
Alias
- UMLS CUI [1]
- C3463824
- UMLS CUI [2]
- C0018939
Description
have secondary aml (aml following chemotherapy or radiation therapy).
Type de données
boolean
Alias
- UMLS CUI [1]
- C0280449
Description
have an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment.
Type de données
boolean
Alias
- UMLS CUI [1]
- C0009488
Description
have a psychiatric disorder(s) that would interfere with consent, study participation or follow-up.
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0021430
- UMLS CUI [1,2]
- C0439801
- UMLS CUI [1,3]
- C0009488
Description
are receiving other chemotherapy or corticosteroids (unless the latter is administered at a low dose for pre-medication purposes or for the treatment of chronic conditions - e.g., rheumatoid arthritis).
Type de données
boolean
Alias
- UMLS CUI [1]
- C0392920
- UMLS CUI [2]
- C0001617
Description
have received prior treatment for leukemia. patients who have received growth factors, cytokine support, leukapheresis, hydroxyurea, or cranial irradiation will be allowed but must discontinue treatment at least 24 hours prior to beginning treatment with clofarabine. if used, hydroxyurea must be discontinued 48 hours prior to the initiation of chemotherapy.
Type de données
boolean
Alias
- UMLS CUI [1]
- C1514463
- UMLS CUI [2]
- C0018284
- UMLS CUI [3]
- C0199974
- UMLS CUI [4]
- C0023416
- UMLS CUI [5]
- C0020402
- UMLS CUI [6]
- C0079172
Description
have any other severe concurrent disease (severe coronary artery disease (nyha class >ii), significant neurological disorder, uncontrolled diabetes, etc.), which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C1321605
- UMLS CUI [1,2]
- C0439801
- UMLS CUI [1,3]
- C0009488
Description
have active central nervous system involvement with leukemia.
Type de données
boolean
Alias
- UMLS CUI [1]
- C1332884
Description
other malignancy within the past year, with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin
Type de données
boolean
Alias
- UMLS CUI [1]
- C0006826
Similar models
Eligibility Acute Myeloid Leukemia NCT00081822
- StudyEvent: Eligibility
C0023487 (UMLS CUI [2])
C3688712 (UMLS CUI [3])
C1515708 (UMLS CUI [4])
C2825131 (UMLS CUI [5])
C0032961 (UMLS CUI [2])
C0700589 (UMLS CUI [3])
C1278039 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
C0018939 (UMLS CUI [2])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0001617 (UMLS CUI [2])
C0018284 (UMLS CUI [2])
C0199974 (UMLS CUI [3])
C0023416 (UMLS CUI [4])
C0020402 (UMLS CUI [5])
C0079172 (UMLS CUI [6])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])